Cardiac effects of dapagliflozin in diabetic rats with subacute exposure

Creative Commons License

Boran T., Karaca B. U., Koroglu A. K., Kaptan E., Ercan F., Özhan G.

ISTANBUL JOURNAL OF PHARMACY, cilt.52, sa.1, ss.8-13, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.26650/istanbuljpharm.2022.1038546
  • Dergi Adı: ISTANBUL JOURNAL OF PHARMACY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.8-13
  • Anahtar Kelimeler: Dapagliflozin, SGLT2 inhibitor, Type 2 diabetes mellitus, Cardio-protection, GLUCOSE COTRANSPORTER 2, OXIDATIVE STRESS, SGLT2 INHIBITOR, TROPONIN-T, CARDIOMYOPATHY, DIET
  • Marmara Üniversitesi Adresli: Evet

Özet

Background and Aims: Dapagliflozin (DAPA) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus (T2DM) as a monotherapy or combination therapy with other antidiabetic medicines. The Food and Drug Administration (FDA) recently approved DAPA to minimize the risk of hospitalization due to heart failure in patients with T2DM because of its antihypertensive and antihyperglycemic activities. However, further study of DAPA is necessary to ensure the safety of patients.